steroid therapy

类固醇治疗
  • 文章类型: Journal Article
    目的:白内障会导致失明,给社区带来健康和经济负担。类固醇诱导的白内障在以前的文献中几乎没有被强调,在沙特阿拉伯西部的普通民众中产生了重新调查这一问题的需求。
    方法:2022年进行了一项横断面研究,使用通过社交媒体平台在目标参与者中分发的在线调查。使用IBM公司收集和统计分析数据2015年发布IBMSPSSStatisticsforWindows,版本23.0。Armonk,纽约:IBM公司软件。
    结果:总体而言,866名受访者(男性=42.5%,女性=57.5%)参加了本次调查(平均年龄=28.08,SD=13)。参与者对类固醇诱导的白内障问题的正确回答显示不充分(低于50%)。此外,大多数参与者(94.23%)对类固醇诱导的白内障了解不足.
    结论:参与者对与长期使用类固醇相关的危险因素及其对白内障的影响的了解程度不够。
    OBJECTIVE: Cataracts consequence blindness to burden and impose health and economic burdens on communities. Steroid-induced cataracts have scarcely been highlighted in previous literature, creating a demand for reinvestigating this issue among the general population of western Saudi Arabia.
    METHODS: A cross-sectional study was conducted in 2022 using an online survey distributed among the target participants via social media platforms. The data were gathered and statistically analyzed using IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp. software.
    RESULTS: Overall, 866 respondents (males = 42.5%, females = 57.5%) were enrolled in this survey (mean age = 28.08, SD = 13). The participants\' correct responses to questions about steroid-induced cataracts showed inadequate representation (below 50%). Additionally, most of the participants (94.23%) had a poor understanding of steroid-induced cataracts.
    CONCLUSIONS: The participants\' level of understanding of the risk factors associated with chronic steroid usage and its impact on cataracts was inadequate.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Randomized Controlled Trial
    目的:评价一种新型非消融性Nd:YAG/Er:YAG双激光治疗外阴硬化性苔藓(LS)的疗效和安全性,并与推荐的一线外用类固醇治疗进行比较。
    方法:一项随机研究者发起的主动对照试验。
    方法:单一三级转诊中心。
    方法:女性外阴LS。
    方法:随机(2:1)对Nd:YAG/Er:YAG激光治疗或局部氯倍他索丙酸治疗。在0、1、2和4个月进行四次激光治疗或减少剂量的类固醇治疗6个月。
    方法:主要结果是基线和6个月之间激光臂客观验证临床LS评分的变化。次要结果是激光耐受性/安全性,症状评分和患者满意度。
    结果:纳入了66名女性,激光组44,类固醇组22。与接受类固醇治疗的患者相比,接受激光治疗的患者的总LS评分降低了-2.34±1.20(95%CI-2.71至-1.98),而接受类固醇治疗的患者则降低了-0.95±0.90(95%CI-1.35至-0.56)(p<0.001)。激光治疗安全且耐受性良好。激光和类固醇组的主观严重程度评分(视觉模拟量表)和外阴阴道症状问卷评分相似地改善,两种治疗方法之间没有显着差异。激光臂的患者满意度高于类固醇臂(p=0.035)。
    结论:非烧蚀双Nd:YAG/Er:YAG激光治疗是安全的,在6个月的随访中显著改善了临床结果和主观症状。这表明激光可能是皮质类固醇治疗的有希望的替代方法。然而,由于该疾病的癌前性质,作者警告定期随访。
    OBJECTIVE: To evaluate the efficacy and safety of a novel non-ablative Nd:YAG/Er:YAG dual laser treatment for vulvar lichen sclerosus (LS) in comparison with the recommended first-line therapy with topical steroid.
    METHODS: A randomised investigator-initiated active-controlled trial.
    METHODS: Single tertiary referral centre.
    METHODS: Women with vulvar LS.
    METHODS: Randomisation (2:1) to Nd:YAG/Er:YAG laser therapy or topical clobetasol proprionate therapy. Four laser treatments at 0, 1, 2 and 4 months or decreasing doses of steroid for 6 months.
    METHODS: The primary outcome was the change in objective validated clinical LS score in the laser arm between baseline and 6 months. Secondary outcomes were laser tolerability/safety, symptom scores and patient satisfaction.
    RESULTS: Sixty-six women were included, 44 in the laser group and 22 in the steroid group. The total LS score decreased by -2.34 ± 1.20 (95% CI -2.71 to -1.98) in women treated with laser compared with a decrease of -0.95 ± 0.90 (95% CI -1.35 to -0.56) in those receiving steroid applications (p < 0.001). Laser treatment was safe and well tolerated. Subjective severity scores (on visual analogue scale) and vulvovaginal symptoms questionnaire scores improved similarly for the laser and steroid arms without significant differences between the two treatments. Patient satisfaction was higher in the laser arm than in the steroid arm (p = 0.035).
    CONCLUSIONS: Non-ablative dual Nd:YAG/Er:YAG laser therapy was safe and significantly improved clinical outcome and subjective symptoms at the 6-month follow up. This suggests that laser may be a promising alternative to corticosteroid therapy. However, the authors caution regular follow ups because of the premalignant nature of the disease.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    UNASSIGNED: The use of steroid therapy in potentially life-threatening neuroinvasive forms of West Nile infection (WNND) is controversial. The aim of this study is to assess the efficacy of steroid therapy in reducing intrahospital mortality, length of stay, and neurological sequelae at discharge.
    UNASSIGNED: This was a multicenter, retrospective, observational study conducted in 5 hospitals in Northern Italy, headed by the Fondazione IRCSS Policlinico San Matteo (Pavia). We extracted all patient data with WNND diagnoses, comparing patients who received steroid treatment with patients who did not receive steroid treatment between January 2014 and January 2022. Comparisons between the 2 groups were performed using chi-square tests for categorical variables and Mann-Whitney tests for non-normal continuous data, and a generalized linear model for the binomial family was carried out.
    UNASSIGNED: Data from 65 WNND patients were extracted. Among these patients, 33 (50.7%) received steroid therapy at any point during their hospitalization. Receiving steroid therapy did not significantly reduce intrahospital mortality (odds ratio [OR], 1.70; 95% CI, 0.3-13.8; P = .89) or neurological sequelae at discharge (OR, 0.53; 95% CI, 0.16-1.76; P = .47).
    UNASSIGNED: Steroid treatment is currently used on a single-case basis in severe WNND. More prospective data are needed to demonstrate a protective effect on mortality and neurological sequelae.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:2019年冠状病毒病(Covid-19)有许多不同的眼部表现。这项研究评估了该疾病和该疾病中使用的类固醇对眼部结构的影响。
    目的:评估Covid-19和类固醇治疗严重感染对眼部结构和脉络膜厚度的影响。
    方法:这项前瞻性研究包括76名因新冠肺炎住院患者的76只眼和30名健康志愿者对照组的30只眼。第一组包括35只眼,因接受类固醇治疗的中度至重度受累而住院,II组包括41只中度受累的眼睛,不需要类固醇治疗,第三组包括30只眼,年龄和性别相匹配的对照组.比较两组患者诊断后第3周和第3个月的眼科检查及影像学检查结果。
    结果:所有参与者的平均年龄为40.2±6.1岁。在诊断Covid-19后的第三周,所有区域的脉络膜厚度(中心凹,鼻部,和时间)在I组中明显高于II组(对于所有,p<0.001)。此外,I组和II组的脉络膜厚度明显高于对照组(对于所有,p<0.001)。第三个月,所有组的脉络膜厚度值相似(对于中央凹,鼻部,和时间;分别为p=0.058,p=0.111,p=0.079)。
    结论:我们的研究结果表明,Covid-19感染通过影响脉络膜层而导致脉络膜增厚,而类固醇治疗在急性期进一步增加了这种厚度。此外,这种增厚在三个月内逆转至正常水平表明该疾病对脉络膜的影响是可逆的。
    BACKGROUND: Coronavirus disease 2019 (Covid-19) has many different ocular manifestations. This study evaluates the effects of the disease and the steroid used in this disease on ocular structures.
    OBJECTIVE:  To evaluate the effects of Covid-19 and the steroids used in the treatment of severe infection on ocular structures and choroidal thickness.
    METHODS: This prospective study included 76 eyes of 76 patients who were hospitalized due to Covid-19 and 30 eyes of 30 healthy volunteering controls. Group I included 35 eyes who were hospitalized due to moderate-to-severe involvement that received steroid treatment, group II included 41 eyes with moderate involvement that did not require steroid treatment, and group III included 30 eyes with age- and gender-matched control subjects. Ophthalmological examination and imaging results of the patients obtained in the third week and third month after the diagnosis were compared between the groups.
    RESULTS: Mean age of all participants was 40.2 ± 6.1 years. In the third week after the diagnosis of Covid-19, choroidal thickness in all regions (subfoveal, nasal, and temporal) was significantly greater in group I than in group II (for all, p<0.001). Moreover, choroidal thicknesses were significantly higher in group I and group II than in the control group (for all, p<0.001). In the third month, all the groups had similar choroidal thickness values (for subfoveal, nasal, and temporal; p=0.058, p=0.111, p=0.079, respectively).
    CONCLUSIONS: Our findings showed that Covid-19 infection causes choroidal thickening by affecting the choroidal layer and that steroid treatment further increases this thickness in the acute period. In addition, the reversal of this thickening to the normal level within a period of three months indicates that the effect of the disease on the choroid is reversible.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    优化严重急性呼吸综合征冠状病毒-2(SARS-CoV-2)感染的管理,识别高危患者并维持治疗剂量强度是侵袭性淋巴瘤患者的重要问题。在本研究中,我们报告了演示文稿,管理,和国际系列91例原发性中枢神经系统淋巴瘤和SARS-CoV-2感染患者的结果。在64例患者的一线治疗之前/期间诊断出SARS-CoV-2,21例随访期间,6例抢救治疗期间。在一线化疗前/期间感染的64例患者中,38人(59%)发展为肺炎,26人(41%)没有清除病毒。在病毒感染和/或高剂量阿糖胞苷治疗之前长期接触类固醇有利于肺炎的发展和病毒的持续存在,并与较差的生存率相关;81%未清除病毒的患者因2019年冠状病毒病早期死亡(COVID-19)。疫苗接种与较低的肺炎发生率和院内死亡率相关。43例(67%)患者开始/恢复化疗,更常见于未发生肺炎的患者,清除了病毒,或者在感染期间没有接受类固醇。病毒持续存在的患者的化疗恢复应谨慎,因为它与较差的生存率相关(6个月,70%和87%,p=0.07)。在随访期间感染的21例患者中,没有一例死于COVID-19,需要与普通人群中的感染受试者类似的措施。
    To optimise management of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection identifying high-risk patients and maintaining treatment dose intensity is an important issue in patients with aggressive lymphomas. In the present study, we report on the presentation, management, and outcome of an international series of 91 patients with primary central nervous system lymphoma and SARS-CoV-2 infection. SARS-CoV-2 was diagnosed before/during first-line treatment in 64 patients, during follow-up in 21, and during salvage therapy in six. Among the 64 patients infected before/during first-line chemotherapy, 38 (59%) developed pneumonia and 26 (41%) did not clear the virus. Prolonged exposure to steroids before viral infection and/or treatment with high-dose cytarabine favoured pneumonia development and virus persistence and were associated with poorer survival; 81% of patients who did not clear virus died early from coronavirus disease 2019 (COVID-19). Vaccination was associated with lower pneumonia incidence and in-hospital mortality. Chemotherapy was initiated/resumed in 43 (67%) patients, more commonly among patients who did not develop pneumonia, cleared the virus, or did not receive steroids during infection. Chemotherapy resumption in patients with viral persistence should be indicated cautiously as it was associated with a poorer survival (6-month, 70% and 87%, p = 0.07). None of the 21 patients infected during follow-up died from COVID-19, requiring similar measures as infected subjects in the general population.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    OBJECTIVE: To systematically describe the short stature of patients with Diamond-Blackfan anemia and to explore factors affecting the height development of patients with Diamond-Blackfan anemia.
    METHODS: This cross-sectional study was conducted at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, and the height, weight, and clinical data of 129 patients with Diamond-Blackfan anemia were collected from June 2020 to September 2020.
    RESULTS: The median height-age-z score (HAZ) of children affected by Diamond-Blackfan anemia was -1.54 (-6.36-1.96). Short stature was found in 37.98% of the patients. Specific Diamond-Blackfan anemia growth curves were developed for weight, height, and body mass index, separately for male and female patients. Multivariable logistic regression models showed that female sex (aOR 4.92; 95% CI 1.29-18.71; P = .0195), underweight (aOR 10.41, 95% CI 1.41-76.98, P = .0217), cardiovascular malformations (aOR 216.65; 95% CI 3.29-14279.79; P = .0118), and RPL11(aOR 29.14; 95% CI 1.18-719.10; P = .0392) or RPS26 (aOR 53.49; 95% CI 1.40-2044.30; P = .0323) mutations were independent risk factors for short stature. In the subgroup of patients who were steroid-dependent, patients with a duration of steroid therapy over 2 years (OR 2.95; 95% CI 1.00-8.66; P = .0494) or maintenance dose of prednisone >0.1 mg/kg per day (OR 3.30; 95% CI 1.02-10.72; P = .0470) had a higher incidence of short stature.
    CONCLUSIONS: Patients with Diamond-Blackfan anemia had a high prevalence of short stature. The risk of short stature increased with age and was associated with sex, underweight, congenital malformations, and RPL11 or RPS26 mutations. The duration of steroid therapy and maintenance dose of steroid was significantly associated with the incidence of short stature in steroid-dependent patients with Diamond-Blackfan anemia.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Topical immunotherapy is widely used in the treatment of alopecia areata (AA). Alopecia areata incognita (AAI) is a relatively common disorder, predominantly affecting females, characterized by widespread hair thinning in the absence of typical alopecic patches. AAI can have a chronic relapsing course and in some cases can be resistant to current standard treatments. Topical immunotherapy has been used in the management of AA with encouraging results, but to date there are no literature studies reporting the efficacy of topical immunotherapy with squaric acid dibutylester (SADBE) in AAI. The aim of our study is to evaluate the efficacy and tolerance of topical immunotherapy with SADBE in AAI not responding to conventional steroid therapy. A total of 12 patients were enrolled in our Hair Disease Outpatient Service, with a proved histological diagnosis of AAI, and resistant to classical steroid therapy. Each patient underwent global photography, pull test, and trichoscopy at beginning and during the follow-ups. The efficacy of topical immunotherapy with SADBE was assessed by evaluating the changes of clinical and trichoscopic signs. Complete regrowth was achieved in 66.7% of cases (8/12), three patients remained unchanged on clinical evaluation but showed subclinical improvement on trichoscopy, whereas one patient progressed and worsened both on clinical and trichoscopic examination. All patients reported scalp diffuse mild erythema and itching the day after the application of SADBE, which were well tolerated. Three patients developed reactive cervical lymphoadenomegaly. No other side effects were observed. Topical immunotherapy with SADBE is widely used in the management of patchy AA and can be considered an effective alternative in resistant AAI, providing visible clinical and trichoscopic improvement in the majority of cases. Further studies are warranted to confirm and validate our findings.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    由于COVID-19,没有常规确定的嗅觉功能障碍治疗方法。盐水冲洗和鼻皮质类固醇治疗是安全和廉价的方法,副作用低。在我们的研究中,我们认为,生理盐水鼻腔冲洗和局部皮质类固醇治疗可用于治疗所有领域的嗅觉丧失患者。共有150名因其他症状或仅有急性气味消失而入院的患者,RT-PCR诊断为COVID-19的患者分为3组。第1组的50名患者没有给予任何额外的治疗。第2组其他50例患者给予生理盐水冲洗治疗;第3组50例患者给予生理盐水冲洗和鼻腔类固醇喷雾剂治疗。“主观嗅觉能力(SOC)”用于患者的嗅觉功能评估。自我评估嗅觉评分(SROS),并在1日记录嗅觉障碍持续时间(ODD),第15天和第30天。第30天接受鼻腔盐水+曲安奈德治疗组的SROS明显高于其他组(p-1-3=0.018,p2-3=0.033)。此外,与其他组相比,本组ODD显著降低(p-1-3=0.022,p2-3=0.028,).发现局部曲安奈德治疗可成功治疗COVID-19引起的嗅觉功能障碍。鼻用类固醇,既便宜又副作用低,可以安全地用于嗅觉损失患者的治疗。
    There is no routinely determined treatment for olfactory dysfunction because of COVID-19. Saline irrigation and nasal corticosteroid treatments are safe and inexpensive methods, and have low side effects. In our study, we argue that saline nasal irrigation and topical corticosteroid treatment can be used in the treatment of patients with olfactory loss in all areas of rhinology. A total of 150 patients who admitted to our clinic with other symptoms or with only acute odor loss, diagnosed with COVID-19 with RT-PCR were divided into 3 equal groups.Fifty patients in Group 1 were not given any extra treatments. The other 50 patients in Group 2 were given saline irrigation for treatment; and the 50 people in Group 3 were given both saline irrigation and nasal steroid spray for treatment. The \"Subjective Olfactory Capability (SOC)\" was used for olfactory function evaluation of patients. Self-Rating Olfactory Score (SROS), and Olfactory Dysfunction Duration (ODD) were recorded on the 1st, 15th and 30th days. SROS of the group receiving Nasal Saline + Triamcinolone Acetonide treatment on the 30th day was significantly higher than in other groups ( p -1-3  = 0.018,  p 2-3  = 0.033). Also, the ODD was significantly reduced in this group compared to other groups ( p -1-3  = 0.022,  p 2-3  = 0.028,). Topical triamcinolone treatment was found to be successful in the treatment of olfactory dysfunction due to COVID-19. Nasal steroids, which are both inexpensive and have low side effect profiles, can be used safely in the treatment of patients with olfactory losses.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    OBJECTIVE: Recurrence rate of nasal polyps is high following endoscopic sinus surgery. To improve the surgical outcome, steroid impregnated nasal dressing is used postoperatively We aimed to compare the effect of Tualang honey impregnated nasal dressing with steroid impregnated nasal dressing on wound healing and surgical outcomes in post endoscopic sinus surgery patients.
    METHODS: A prospective, randomized, controlled trial was carried out at two tertiary hospitals. 32 patients diagnosed with chronic rhinosinusitis and had underwent endoscopic sinus surgery were enrolled. The study group received 2 mL of Tualang honey nasal dressing and the control group received nasal dressing with 2 mL of triamcinolone 20 mg/mL as positive control. A 2 cm nasal dressing was placed longitudinally into the middle meatuses of both nasal cavities. Postoperative healing assessments of edema, crusting, secretions, scarring and symptoms were performed at postoperative day 7, 14, 28 and at 3 months using Sinonasal Outcome Test 22 questionnaire and modified Lund-Kennedy scoring system.
    RESULTS: There were no significant differences noted in the scores of Sinonasal Outcome Test 22 and modified Lund-Kennedy at Day 7, 14 and 28 (p>0.05) for both groups. At 3rd month, patients in the triamcinolone group had lesser symptoms and better endoscopic findings (p<0.05).
    CONCLUSIONS: Tualang honey is not as effective as steroid in achieving good wound healing and surgical outcomes in post endoscopic sinus surgery patients. Thus, it is not suitable as a substitute for steroid to reduce symptoms and prevent recurrence of disease.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    Objectives: Acupuncture, widely used in Chinese society, has been studied as an adjunct treatment of idiopathic sudden sensorineural hearing loss (ISSNHL). The purpose of this study is to investigate the effectiveness of combined acupuncture and hyperbaric oxygen therapy (HBOT) with conventional steroid therapy for ISSNHL. Methods: This retrospective chart review enrolled 154 patients who met the ISSNHL criteria and were categorized into three groups according to the different treatment regimens. Among these patients, 43 underwent steroid therapy only (S) group, 74 received steroid and HBOT (S-H) group, and the remaining 37 were treated with combined acupuncture-HBOT in addition to steroid therapy (S-H-A) group. The outcome was determined by comparing the differences in pure-tone thresholds and absolute hearing gains after treatment calculated at each audiometric octave frequency or grouped frequencies of audiograms. Hearing recoveries classified into three grades: complete, partial, and poor were also analyzed and compared among different treatment groups. Results: All subjects presented with initial severe hearing loss with averaged hearing thresholds >70 dB. The S-H-A group exhibited good hearing improvement outcomes at each audiometric octave frequency and grouped frequencies of audiograms, with greater hearing gain and had more favorable outcomes in hearing recovery grades compared with the S group and the S-H group. Conclusions: The results obtained in this study revealed a preliminary finding of ISSNHL patients benefiting from combined acupuncture, HBOT, and conventional steroid therapy. Acupuncture is a safe and nonpharmacologic treatment option and can be considered as an initial treatment strategy in such a clinical scenario.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号